Phase III Soft Tissue Sarcoma Trials: Success or Failure?
MetadataShow full item record
OPINION STATEMENT: Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for advanced soft tissue sarcoma. Both of these trials' designs were informed by phase II data that guided the selection of sensitive STS diagnoses, enabling the demonstration of benefit in certain subtypes. A number of other phase III trials reported in the last 18 months have seemingly fit into a recurrent pattern of failure-promising efficacy signals in earlier phase studies being lost in the survival follow-up of large, highly heterogeneous cohorts. Greater effort is needed to identify histological and molecularly defined subgroups associated with differential treatment response in order to avoid the tremendous disappointment and loss of resources associated with a failed phase III trial. Additionally, improvements in available treatment of advanced STS have underpinned a prolongation in overall survival (OS). Consequently, surrogate efficacy endpoints are of increasing importance to STS drug trials. Whilst progression-free survival (PFS) should arguably replace overall survival as the primary endpoint of choice in first-line studies, more work is required to provide definitive validation of surrogacy, as well as developing more sophisticated techniques of assessing radiological response and expanding the inclusion of quality-of-life-related endpoints.
Version of record
Clinical trial design
Soft tissue sarcoma
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials, Phase III as Topic
Randomized Controlled Trials as Topic
Standard of Care
Sarcoma Clinical Trials (R Jones)
Curr Treat Options Oncol, 18 (3), pp. 19 - ?
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians’ Practices across Six Randomised Controlled Trials Rooshenas, L; Elliott, D; Wade, J; Jepson, M; Paramasivan, S; Strong, S; Wilson, C; Beard, D; Blazeby, JM; Birtle, A; Halliday, A; Rogers, CA; Stein, R; Donovan, JL (2016-10-18)
Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit Murad, MH; Guyatt, GH; Domecq, JP; Vernooij, RW; Erwin, PJ; Meerpohl, JJ; Prutsky, GJ; Akl, EA; Mueller, K; Bassler, D; Schandelmaier, S; Walter, SD; Busse, JW; Kasenda, B; Pagano, G; Pardo-Hernandez, H; Montori, VM; Wang, Z; Briel, M (2017-02)
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Vormoor, B; Veal, GJ; Griffin, MJ; Boddy, AV; Irving, J; Minto, L; Case, M; Banerji, U; Swales, KE; Tall, JR; Moore, AS; Toguchi, M; Acton, G; Dyer, K; Schwab, C; Harrison, CJ; Grainger, JD; Lancaster, D; Kearns, P; Hargrave, D; Vormoor, J (2017-06)Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and ...